CH Biotech R&D Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for CH Biotech R&D.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Chemicals earnings growth | 52.6% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 30 Jan 2024 |
Recent future growth updates
No updates
Recent updates
CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt
Apr 05A Look At CH Biotech R&D's (GTSM:6534) Share Price Returns
Mar 18Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Feb 09Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting Picture
Jan 11Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?
Dec 15Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend Yield
Nov 24Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 1,616 | N/A | 344 | 524 | 2 |
12/31/2023 | 1,515 | 463 | 544 | 659 | N/A |
9/30/2023 | 1,425 | 430 | 463 | 620 | N/A |
6/30/2023 | 1,407 | 445 | 507 | 630 | N/A |
3/31/2023 | 1,644 | 589 | 614 | 731 | N/A |
12/31/2022 | 1,434 | 465 | 582 | 699 | N/A |
9/30/2022 | 1,593 | 619 | 697 | 764 | N/A |
6/30/2022 | 1,635 | 647 | 653 | 727 | N/A |
3/31/2022 | 1,274 | 437 | 227 | 307 | N/A |
12/31/2021 | 1,019 | 291 | 192 | 264 | N/A |
9/30/2021 | 875 | 208 | 275 | 346 | N/A |
6/30/2021 | 810 | 170 | 232 | 313 | N/A |
3/31/2021 | 756 | 135 | 178 | 273 | N/A |
12/31/2020 | 702 | 100 | 124 | 233 | N/A |
9/30/2020 | 679 | 79 | 44 | 165 | N/A |
6/30/2020 | 656 | 57 | -37 | 97 | N/A |
3/31/2020 | 748 | 124 | 65 | 201 | N/A |
12/31/2019 | 841 | 190 | 166 | 305 | N/A |
9/30/2019 | 876 | 224 | 144 | 331 | N/A |
6/30/2019 | 912 | 258 | 122 | 356 | N/A |
3/31/2019 | 896 | 272 | -40 | 304 | N/A |
12/31/2018 | 880 | 285 | -202 | 252 | N/A |
9/30/2018 | 861 | 294 | -323 | 292 | N/A |
6/30/2018 | 841 | 303 | -444 | 332 | N/A |
3/31/2018 | 764 | 258 | -251 | 562 | N/A |
12/31/2017 | 781 | 290 | -568 | 384 | N/A |
9/30/2017 | 828 | 330 | N/A | 361 | N/A |
6/30/2017 | 805 | 319 | N/A | 385 | N/A |
3/31/2017 | 762 | 307 | N/A | 167 | N/A |
12/31/2016 | 698 | 258 | N/A | 244 | N/A |
9/30/2016 | 674 | 238 | N/A | 276 | N/A |
6/30/2016 | 664 | 252 | N/A | 295 | N/A |
3/31/2016 | 609 | 228 | N/A | 198 | N/A |
12/31/2015 | 511 | 205 | N/A | 259 | N/A |
9/30/2015 | 430 | 199 | N/A | 206 | N/A |
6/30/2015 | 404 | 209 | N/A | 120 | N/A |
3/31/2015 | 312 | 176 | N/A | 127 | N/A |
12/31/2014 | 192 | 104 | N/A | 87 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 6534's forecast earnings growth is above the savings rate (1%).
Earnings vs Market: Insufficient data to determine if 6534's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if 6534's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 6534's revenue is forecast to grow faster than the TW market.
High Growth Revenue: Insufficient data to determine if 6534's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6534's Return on Equity is forecast to be high in 3 years time